Literature DB >> 16909127

E2A protein degradation by the ubiquitin-proteasome system is stage-dependent during muscle differentiation.

L Sun1, J S Trausch-Azar, A Ciechanover, A L Schwartz.   

Abstract

The E2A proteins are basic helix-loop-helix transcription factors that regulate proliferation and differentiation in many cell types. In muscle cells, the E2A proteins form heterodimers with muscle regulatory factors such as MyoD, which then bind to DNA and regulate the transcription of target genes essential for muscle differentiation. We now demonstrate that E2A proteins are primarily localized in the nucleus in both C2C12 myoblasts and myotubes, and are degraded by the ubiquitin proteasome system evidenced by stabilization following treatment with the proteasome inhibitor, MG132. During the differentiation from myoblast to myotube, the cellular abundance of E2A proteins is relatively unaltered, despite significant changes (each approximately 5-fold) in the relative rates of protein synthesis and protein degradation via the ubiquitin-proteasome system. The rate of ubiquitin-proteasome-mediated E2A protein degradation depends on the myogenic differentiation state (t 1/2 approximately 2 h in proliferating myoblasts versus t 1/2 > 10 h in differentiated myotubes), and is also associated with cell cycle in non-muscle cells. Our findings reveal an important role for both translational and post-translational regulatory mechanisms in mediating the complex program of muscle differentiation determined by the E2A proteins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16909127     DOI: 10.1038/sj.onc.1209793

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Small molecule screen reveals regulation of survival motor neuron protein abundance by Ras proteins.

Authors:  Reka R Letso; Andras J Bauer; Mitchell R Lunn; Wan Seok Yang; Brent R Stockwell
Journal:  ACS Chem Biol       Date:  2013-03-29       Impact factor: 5.100

2.  Calcium regulation of myogenesis by differential calmodulin inhibition of basic helix-loop-helix transcription factors.

Authors:  Jannek Hauser; Juha Saarikettu; Thomas Grundström
Journal:  Mol Biol Cell       Date:  2008-03-19       Impact factor: 4.138

3.  Basic helix loop helix (bHLH) transcription factor 3 (TCF3, E2A) is regulated by androgens in prostate cancer cells.

Authors:  Divya Patel; Swathi Chinaranagari; Jaideep Chaudhary
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

4.  Control of myogenesis by rodent SINE-containing lncRNAs.

Authors:  Jiashi Wang; Chenguang Gong; Lynne E Maquat
Journal:  Genes Dev       Date:  2013-04-04       Impact factor: 11.361

5.  The E3 ubiquitin ligase specificity subunit ASB2beta is a novel regulator of muscle differentiation that targets filamin B to proteasomal degradation.

Authors:  N F Bello; I Lamsoul; M L Heuzé; A Métais; G Moreaux; D A Calderwood; D Duprez; C Moog-Lutz; P G Lutz
Journal:  Cell Death Differ       Date:  2009-03-20       Impact factor: 15.828

Review 6.  Ubiquitination and the Ubiquitin-Proteasome System as regulators of transcription and transcription factors in epithelial mesenchymal transition of cancer.

Authors:  Ioannis A Voutsadakis
Journal:  Tumour Biol       Date:  2012-03-06

7.  A novel conserved isoform of the ubiquitin ligase UFD2a/UBE4B is expressed exclusively in mature striated muscle cells.

Authors:  Andrew L Mammen; James A Mahoney; Amanda St Germain; Nisha Badders; J Paul Taylor; Antony Rosen; Sarah Spinette
Journal:  PLoS One       Date:  2011-12-09       Impact factor: 3.240

Review 8.  The beneficial role of proteolysis in skeletal muscle growth and stress adaptation.

Authors:  Ryan A V Bell; Mohammad Al-Khalaf; Lynn A Megeney
Journal:  Skelet Muscle       Date:  2016-04-06       Impact factor: 4.912

9.  Global mapping of DNA methylation in mouse promoters reveals epigenetic reprogramming of pluripotency genes.

Authors:  Cassandra R Farthing; Gabriella Ficz; Ray Kit Ng; Chun-Fung Chan; Simon Andrews; Wendy Dean; Myriam Hemberger; Wolf Reik
Journal:  PLoS Genet       Date:  2008-06-27       Impact factor: 5.917

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.